Recent Quotes (30 days)

You have no recent quotes
chg | %

BTG plc  

(Public, LON:BTG)   Watch this stock  
Find more results forLON:BGC
+5.00 (0.81%)
Nov 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 607.07 - 625.50
52 week 504.00 - 835.87
Open 611.00
Vol / Avg. 270,830.00/661,182.00
Mkt cap 2,376.02M*
P/E 52.82
Div/yield     -
EPS 0.12*
Shares 382.95M
Beta     -
Inst. own     -
Nov 18, 2015
BTG PLC at Jefferies Autumn Global Healthcare Conference
Nov 17, 2015
BTG PLC at Barclays Global Income Corporate Day
Sep 25, 2015
BTG PLC at Citi UK SMID and Travel & Leisure Conference

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 22.34% 9.14%
Operating margin 16.99% 9.22%
EBITD margin - 18.35%
Return on average assets 9.62% 3.82%
Return on average equity 13.09% 5.21%
Employees 986 -
CDP Score - 76 D


5 Fleet Place
United Kingdom - Map
+44-20-75750000 (Phone)
+44-20-75750010 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company's Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company's Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company's Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company's subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.

Officers and directors

Dame Pamela Louise Makin Ph.D. Chief Executive Officer, Executive Director
Age: 54
Rolf B. Soderstrom Chief Financial Officer, Executive Director
Melanie G. Lee Ph.D. Chief Scientific Officer
Age: 57
Paul Mussenden Company Secretary
Garry Andrew Watts MBE Non-Executive Chairman of the Board
Age: 58
Susan Elizabeth Foden Ph.D. Non-Executive Director
Age: 62
Giles F. B. Kerr Senior Independent Non-Executive Director
Ian F. R. Much Independent Non-Executive Director
W. James O'Shea Independent Non-Executive Director